C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the... The drug is composed of an IL-6–binding trimer and a IgG-binding domain.
- Mechanism
- Curator reviewed
C326 is a novel protein therapeutic, designed to inhibit the function of interleukin-6 (IL-6), a pro-inflammatory cytokine that stimulates an immune response to trauma and has been shown to play a role in multiple disease indications. By inhibiting IL-6, C326 is designed to reduce or prevent symptoms associated with autoimmunity and inflammation. C326, as an Avimer drug candidate, has a unique structure that distinguishes it from antibodies, antibody fragments and other therapeutic proteins. Avimer proteins are much smaller than most therapeutic proteins and antibodies and their specificity and avidity make them particularly attractive as drug candidates.
- Primary indication
- Investigated for use/treatment in inflammatory disorders (unspecified).Curator reviewed
- Code names
- AMG-220
Resolves to
What you can answer from here — as of March 06, 2025
Which drugs share a target with C326, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account